Postdoctoral Research Scientist
I completed my DPhil in Clinical Pharmacology from the Department of Oncology, University of Oxford, where the focus of my thesis was the production of cancer vaccines based on different viral vectors, and assessing the immune responses against cancer and viral antigens. During the course of my research, I became interested in cancer immunology and the tumour microenvironment.
My first postdoctoral project was undertaken with Professor Alison Banham (NDCLS/RDM) where I investigated the role of transcription factor FOXP1 in immune evasion in diffuse large B cell lymphoma, through CRISPR-Cas9 knockouts and RNA sequencing. I subsequently moved to Dr Gillian Farnie's group at the Botnar Research Centre (NDORMS), where I studied the effects of MLLT1 histone reader in breast cancer and acute myeloid leukaemia using RNA and ChIP sequencing. I was also part of a multi-disciplinary collaboration to develop novel small molecule inhibitors targeting MLLT1 in acute leukaemia.
In 2020 I joined NDM to work in Professor Tao Dong's and Professor Julian Knight's groups. My current focus is on characterising T cell responses against SARS-CoV-2 through single cell RNA sequencing and TCR repertoire analysis.
Felce SL. et al, (2020), Front Oncol, 10
Moustakim M. et al, (2018), Angew Chem Int Ed Engl, 57, 16302 - 16307
Brown PJ. et al, (2016), Leukemia, 30, 605 - 616
Felce SL. et al, (2020), Wellcome Open Research, 5, 42 - 42